CLINICAL_TRIALS
trial_result
· 2022-08-23
Clinical Trial Update: Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma [Phase 1]
Summary
Phase 1 trial update of LMB-100, a mesothelin-targeted immunotoxin, in people with malignant mesothelioma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma | Phase 1 | Status: COMPLETED | Results posted: 2022-08-23